Tag: Thryv Therapeutics

Thryv Therapeutics Receives FDA IND Clearance of THRV-1268 for Clinical Programs in Heart Failure and Atrial Fibrillation and Presents Results of SGK1 Inhibition Combined with Jardiance (empagliflozin), an SGLT2 inhibitor, in a Pressure Overload Heart Failure Model at ESC Congress 2025

Rhythm by 0 comments

MONTREAL, Sept. 8, 2025 /PRNewswire/ – Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing a series of novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors for cardiovascular diseases, today announced the presentation of preclinical results demonstrating…

Continue Reading →